
Biopharmaceutical executive with 20+ years of experience shaping global oncology portfolio strategy, commercialization, and lifecycle value for leading pharmaceutical organizations. Trusted advisor to executive leadership on multi-billion-dollar pipeline investments, global launch strategy, pricing, and operating model design. Deep expertise across oncology, hematology, immunology, and advanced biologics, translating breakthrough science into blockbuster global franchises.
Shaped C-suite portfolio decisions supporting $10B peak sales opportunity
Guided prioritization of 50 Phase II/III clinical trials to optimize R&D investment
Shaped C-suite pricing & access strategy, driving multi‑billion‑dollar lifecycle value
Partnered with Legal/IP on patent strategy unlocking multi‑billion‑dollar opportunity
Owned P&L portfolios up to $3B, delivering sustained growth and market share gains
Led commercialization strategy for 11 launches, 5 in oncology including 4 blockbusters